Vincerx Pharma To Be Acquired by Private Biotech, Cut Headcount

Dow Jones

28 Dec 2024

By Ben Glickman

Vincerx Pharma said it had agreed to merge with private biotechnology company Oqory after a review of strategic alternatives.

The biotech company said that it would also implement cost-cutting measures, including layoffs. Chief Executive Ahmed Hamdy and Chief Financial Officer Alexander Seelenberger have both stepped down in connection with the layoffs, the company said.

Vincerx said that the deal includes a fully diluted equity value of $13.66 million for existing Vincerx stockholders. Current shareholders are expected to own about 5% of the combined company, with the remainder held by Oqory shareholders.

The company will launch a stock offering of at least $20 million as part of the deal. Certain investors in Oqory agreed to provide interim financing of $1.5 million to Vincerx.

The merger is subject to closing conditions, which includes the completion of the equity offering and the continued listing of Vincerx stock.

In the interim, operating chief Raquel Izumi will serve as acting CEO in a consulting capacity. Controller Kevin Hass has taken over as acting CFO.

Oqory's pipeline of therapies includes multiple antibody-drug conjugate programs, which are a form of cancer treatment. Vincerx is developing several different forms of cancer treatment.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

December 27, 2024 16:28 ET (21:28 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2494358079"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2494358079\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2494358079?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-28 05:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2494358079","market":"sg","top_or_hot":-1,"title":"Vincerx Pharma To Be Acquired by Private Biotech, Cut Headcount","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Ben Glickman \n</p>\n<pre>\n \n</pre>\n<p>\n  Vincerx Pharma said it had agreed to merge with private biotechnology company Oqory after a review of strategic alternatives. \n</p>\n<p>\n  The biotech company said that it would also implement cost-cutting measures, including layoffs. Chief Executive Ahmed Hamdy and Chief Financial Officer Alexander Seelenberger have both stepped down in connection with the layoffs, the company said. \n</p>\n<p>\n  Vincerx said that the deal includes a fully diluted equity value of $13.66 million for existing Vincerx stockholders. Current shareholders are expected to own about 5% of the combined company, with the remainder held by Oqory shareholders. \n</p>\n<p>\n  The company will launch a stock offering of at least $20 million as part of the deal. Certain investors in Oqory agreed to provide interim financing of $1.5 million to Vincerx. \n</p>\n<p>\n  The merger is subject to closing conditions, which includes the completion of the equity offering and the continued listing of Vincerx stock. \n</p>\n<p>\n  In the interim, operating chief Raquel Izumi will serve as acting CEO in a consulting capacity. Controller Kevin Hass has taken over as acting CFO. \n</p>\n<p>\n  Oqory's pipeline of therapies includes multiple antibody-drug conjugate programs, which are a form of cancer treatment. Vincerx is developing several different forms of cancer treatment. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Ben Glickman at ben.glickman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 27, 2024 16:28 ET (21:28 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vincerx Pharma To Be Acquired by Private Biotech, Cut Headcount</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVincerx Pharma To Be Acquired by Private Biotech, Cut Headcount\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-28 05:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Ben Glickman \n</p>\n<pre>\n \n</pre>\n<p>\n  Vincerx Pharma said it had agreed to merge with private biotechnology company Oqory after a review of strategic alternatives. \n</p>\n<p>\n  The biotech company said that it would also implement cost-cutting measures, including layoffs. Chief Executive Ahmed Hamdy and Chief Financial Officer Alexander Seelenberger have both stepped down in connection with the layoffs, the company said. \n</p>\n<p>\n  Vincerx said that the deal includes a fully diluted equity value of $13.66 million for existing Vincerx stockholders. Current shareholders are expected to own about 5% of the combined company, with the remainder held by Oqory shareholders. \n</p>\n<p>\n  The company will launch a stock offering of at least $20 million as part of the deal. Certain investors in Oqory agreed to provide interim financing of $1.5 million to Vincerx. \n</p>\n<p>\n  The merger is subject to closing conditions, which includes the completion of the equity offering and the continued listing of Vincerx stock. \n</p>\n<p>\n  In the interim, operating chief Raquel Izumi will serve as acting CEO in a consulting capacity. Controller Kevin Hass has taken over as acting CFO. \n</p>\n<p>\n  Oqory's pipeline of therapies includes multiple antibody-drug conjugate programs, which are a form of cancer treatment. Vincerx is developing several different forms of cancer treatment. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Ben Glickman at ben.glickman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 27, 2024 16:28 ET (21:28 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VINC","symbol_name":"Vincera Pharma, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2494358079","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2494358079","pubTimestamp":1735334880,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Vincerx Pharma said it had agreed to merge with private biotechnology company Oqory after a review of strategic alternatives.The biotech company said that it would also implement cost-cutting measures, including layoffs. Chief Executive Ahmed Hamdy and Chief Financial Officer Alexander Seelenberger have both stepped down in connection with the layoffs, the company said.Vincerx said that the deal includes a fully diluted equity value of $13.66 million for existing Vincerx stockholders. Current shareholders are expected to own about 5% of the combined company, with the remainder held by Oqory shareholders.The company will launch a stock offering of at least $20 million as part of the deal. Certain investors in Oqory agreed to provide interim financing of $1.5 million to Vincerx.The merger is subject to closing conditions, which includes the completion of the equity offering and the continued listing of Vincerx stock.In the interim, operating chief Raquel Izumi will serve as acting CEO in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VINC":"Vincera Pharma, Inc.","BK4139":"生物科技"},"translate_title":"Vincerx Pharma将被私营生物技术公司收购，裁员","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VINC":0.9},"content_text":"By Ben Glickman \n\n\n \n\n\n  Vincerx Pharma said it had agreed to merge with private biotechnology company Oqory after a review of strategic alternatives. \n\n\n  The biotech company said that it would also implement cost-cutting measures, including layoffs. Chief Executive Ahmed Hamdy and Chief Financial Officer Alexander Seelenberger have both stepped down in connection with the layoffs, the company said. \n\n\n  Vincerx said that the deal includes a fully diluted equity value of $13.66 million for existing Vincerx stockholders. Current shareholders are expected to own about 5% of the combined company, with the remainder held by Oqory shareholders. \n\n\n  The company will launch a stock offering of at least $20 million as part of the deal. Certain investors in Oqory agreed to provide interim financing of $1.5 million to Vincerx. \n\n\n  The merger is subject to closing conditions, which includes the completion of the equity offering and the continued listing of Vincerx stock. \n\n\n  In the interim, operating chief Raquel Izumi will serve as acting CEO in a consulting capacity. Controller Kevin Hass has taken over as acting CFO. \n\n\n  Oqory's pipeline of therapies includes multiple antibody-drug conjugate programs, which are a form of cancer treatment. Vincerx is developing several different forms of cancer treatment. \n\n\n \n\n\n  Write to Ben Glickman at ben.glickman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 27, 2024 16:28 ET (21:28 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding,corporation","news_rank":0,"symbols":[],"gpt_button":1}}}